Gilla Kaplan
CIK: 0001247024
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 2, 2026AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Mar 26, 2026TYRA
Tyra Biosciences, Inc.
Disposition(D)Direct53.2K shares at avg. $37.75$2.0M - Mar 26, 2026TYRA
Tyra Biosciences, Inc.
Exercise(M)Direct53.2K shares at avg. $2.25$120K - Mar 25, 2026TYRA
Tyra Biosciences, Inc.
Exercise(M)Direct14.3K shares at avg. $2.25$32K - Mar 25, 2026TYRA
Tyra Biosciences, Inc.
Sale(S)Direct14.3K shares at avg. $36.97$529K - Jun 18, 2025TYRA
Tyra Biosciences, Inc.
Sale(S)Direct9.6K shares at avg. $9.78$94K - Jun 17, 2025TYRA
Tyra Biosciences, Inc.
Sale(S)Direct10 shares at avg. $10.35$103.5 - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Jun 16, 2025TYRA
Tyra Biosciences, Inc.
Sale(S)Direct6.8K shares at avg. $10.38$71K - Jun 13, 2025TYRA
Tyra Biosciences, Inc.
Sale(S)Direct15K shares at avg. $10.31$155K - Jun 12, 2025TYRA
Tyra Biosciences, Inc.
Sale(S)Direct30K shares at avg. $10.31$309K - May 29, 2025TYRA
Tyra Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
22.2K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
Exercise(M)Direct3.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 2, 2026 |  AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Mar 26, 2026 |  TYRA Tyra Biosciences, Inc. | Disposition(D) | 53,172 | $37.75 | $2,007,153 | Direct |
| Mar 26, 2026 | TYRA Tyra Biosciences, Inc. | Exercise(M) | 53,172 | $2.25 | $119,637 | Direct |
| Mar 25, 2026 | TYRA Tyra Biosciences, Inc. | Exercise(M) | 14,295 | $2.25 | $32,164 | Direct |
| Mar 25, 2026 | TYRA Tyra Biosciences, Inc. | Sale(S) | 14,295 | $36.97 | $528,506 | Direct |
| Jun 18, 2025 | TYRA Tyra Biosciences, Inc. | Sale(S) | 9,568 | $9.78 | $93,596 | Direct |
| Jun 17, 2025 | TYRA Tyra Biosciences, Inc. | Sale(S) | 10 | $10.35 | $104 | Direct |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Jun 16, 2025 | TYRA Tyra Biosciences, Inc. | Sale(S) | 6,814 | $10.38 | $70,726 | Direct |
| Jun 13, 2025 | TYRA Tyra Biosciences, Inc. | Sale(S) | 15,000 | $10.31 | $154,583 | Direct |
| Jun 12, 2025 | TYRA Tyra Biosciences, Inc. | Sale(S) | 30,000 | $10.31 | $309,255 | Direct |
| May 29, 2025 | TYRA Tyra Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 22,200 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise(M) | 3,167 | - | - | Direct |
1-13 of 13 transactions
About KAPLAN GILLA
KAPLAN GILLA (SEC CIK 0001247024) files insider reports with the SEC as Director of Avalo Therapeutics, Inc. (AVTX) and Director of Tyra Biosciences, Inc. (TYRA).
Signal8 holds 7 ownership filings by KAPLAN GILLA, all Form 4s, filed between Apr 1, 2025 and Jun 4, 2026. Those filings report 13 transactions, from Mar 28, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on KAPLAN GILLA's filings is in WAYNE, PA.
Recent filings by KAPLAN GILLA
- Jun 2, 2026: Grant or award of AVTX derivative securities (Form 4, code A).
- Mar 26, 2026: Disposition to issuer transaction of TYRA shares (Form 4, code D).
- Mar 26, 2026: Option exercise of TYRA shares (Form 4, code M).
- Mar 25, 2026: Option exercise of TYRA shares (Form 4, code M).
- Mar 25, 2026: Open-market sale of TYRA shares (Form 4, code S).
Other insiders filing for Avalo Therapeutics, Inc. (AVTX)
- Jain Rita, Director
- Lind Kevin Robert, Director
- Philip Ron M, Director
- Sullivan Christopher Ryan, Chief Financial Officer
- Doyle Mittie, Chief Medical Officer
- Riley Jennifer, Chief Strategy Officer